Replies to post #1448 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Tinkershaw,

Instead of Teva looking at Momenta in many ways I would think a generic copax might entice interest from someone like Biogen or Merck Kgaa.

I'm sure the Sandoz agreement would have to be looked at in detail to see what it allows or entails.

[DewDiligence]

It makes no difference whether MYL’s Copaxone is a serious contender; regardless, the FTC would view a Teva acquisition of MNTA as reducing competition in the US Copaxone market and would nix such a deal.

I’m as certain of the above as I’ve been of anything I’ve ever posted on iHub.